Expert Analysis

Clinical Updates in HBV Treatment

Source: CCO Independent Conference Coverage of the 2006 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Clinical Updates in HBV Treatment

Faculty:

Geoffrey M. Dusheiko, MD, FCP(SA), FRCP
Robert G. Gish, MD
Marion G. Peters, MD

CME CREDIT INFORMATION

Release Date: 12/13/06

Expiration Date: 12/12/07

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.5 Nursing CE credits

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount clinical data on long-term therapy for the treatment of chronic hepatitis B
Describe predictors of various therapeutic endpoints in patients receiving HBV therapy
Review data regarding management strategies for patients with lamivudine resistance
Discuss the use of noninvasive fibrosis markers in inactive HBV carriers

Topics covered include:

ETV-901: Long-term Efficacy of Entecavir
Predictors of HBsAg Loss in Patients Treated With Entecavir or Lamivudine
Year 3 Analysis of Entecavir Resistance
GLOBE: Efficacy of Telbivudine vs Lamivudine
Efficacy of Telbivudine vs Adefovir
Switching vs Adding Adefovir in Patients Resistant to Lamivudine
Sustained Responses Following Cessation of Long-term Adefovir
Peginterferon Durability After Treatment Cessation
Predictive Value of HBV DNA for Lamivudine Response
HBV DNA Suppression and T-Cell Reactivity
Noninvasive Fibrosis Measurement in Inactive HBV Carriers

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.